Cargando…

Systematic analysis of design and stratification for phase III trials in first‐line advanced non‐small cell lung cancer

BACKGROUND: A recent study reviewed phase III trials of first‐line advanced non‐small cell lung cancer (NSCLC) conducted from 1981 to 2010, and provided trends in the study outcome. However, such trials have never been analyzed in detail for design and stratification factors. METHODS: Phase III stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komiya, Takefumi, Perez, Raymond P., Erickson, Kirsten D., Huang, Chao H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718121/ https://www.ncbi.nlm.nih.gov/pubmed/26813229 http://dx.doi.org/10.1111/1759-7714.12276

Ejemplares similares

Impact of Liver Metastasis on First-Line Immunotherapy in Stage IV Non-Small Cell Lung Cancer
por: Komiya, Takefumi, et al.
Publicado: (2023)

Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series
por: Dasari, Srikiran, et al.
Publicado: (2022)

Recent trends in use of adjuvant chemotherapy in elderly stage II–III non-small cell lung cancer
por: Komiya, Takefumi, et al.
Publicado: (2020)

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial
por: Wachters, F M, et al.
Publicado: (2003)

Clinical impact of number of lymph nodes dissected on postoperative survival in node-negative small cell lung cancer
por: Takamori, Shinkichi, et al.
Publicado: (2022)

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial
por: Jabbour, Salma K., et al.
Publicado: (2021)

Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation
por: Bachy, Emmanuel, et al.
Publicado: (2021)

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
por: Sun, Yan, et al.
Publicado: (2016)

Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non‐small‐cell lung cancer: Real‐world data from 86 173 patients
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
por: Cappuzzo, F, et al.
Publicado: (2005)

Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
por: Johnson, Melissa L., et al.
Publicado: (2023)

Exclusion of Patients with Autoimmune Disease in Lung Cancer Clinical Trials
por: Khan, Shamsher S, et al.
Publicado: (2023)

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
por: Vardy, Janette, et al.
Publicado: (2009)

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer
por: Ramalingam, Suresh S., et al.
Publicado: (2021)

Advances in the Treatment of Mucoepidermoid Carcinoma
por: Sama, Srikar, et al.
Publicado: (2022)

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
por: Ramalingam, Suresh S., et al.
Publicado: (2021)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi, Shipra, et al.
Publicado: (2015)

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer
por: Yang, Szu‐Chun, et al.
Publicado: (2023)

The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer
por: Middleton, G., et al.
Publicado: (2015)

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
por: Negoro, S, et al.
Publicado: (2003)

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
por: Seckl, Michael J., et al.
Publicado: (2017)

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
por: Nan, Xueli, et al.
Publicado: (2017)

An Overview of Lung and Breast Cancer Using the National Cancer Database
por: Deshotels, Leigh, et al.
Publicado: (2020)

Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung
por: Komiya, Takefumi, et al.
Publicado: (2021)

Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
por: Pereira, José Rodrigues, et al.
Publicado: (2013)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2021)

The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
por: Spagnuolo, Alessia, et al.
Publicado: (2023)

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients
por: Kim, Lucia, et al.
Publicado: (2017)

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
por: Feliciano, Josephine Louella, et al.
Publicado: (2023)

Trends in phase III randomized controlled clinical trials on the treatment of advanced non‐small‐cell lung cancer
por: Fernández‐López, Cristina, et al.
Publicado: (2016)

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012)

Randomized phase III study comparing the first-line chemotherapy regimens in patients with driver mutation-negative advanced non-small cell lung cancer and poor performance status complicated with chronic obstructive pulmonary disease
por: Gao, Guoying, et al.
Publicado: (2021)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
por: Lee, Siow Ming, et al.
Publicado: (2012)

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
por: Komiya, Takefumi, et al.
Publicado: (2018)

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2019)

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
por: Paz-Ares, L, et al.
Publicado: (2008)

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
por: Asahina, H, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_vu26b3n6r707smpgvnnku3cb0u